# Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)

> **NCT06380738** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 250 (estimated)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06380738
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-14
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06380738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06380738, "Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06380738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*